CN Mobile Logo



ASCO 2016 Genitourinary Cancers Symposium

Cancer Network presents exclusive coverage from the American Society of Clinical Oncology (ASCO) 2016 Genitourinary Cancers Symposium, held January 7–9 in San Francisco. We’ll bring you reports as we cover the latest research, trials, scientific advances, and controversies that are changing the way genitourinary cancers are managed and treated.


The FDA has granted orphan drug designation for the novel agent known as TRC105, in development by Tracon Pharmaceuticals, for the treatment of soft-tissue sarcoma.

The US Food and Drug Administration announced the approval of eribulin (Halaven) for the treatment of unresectable, metastatic liposarcoma in patients who have received prior chemotherapy with an anthracycline.

The aim of this review is to discuss current neoadjuvant treatment options for soft-tissue sarcomas.

Improvements in neoadjuvant therapy for soft-tissue sarcomas will require the development of more efficacious systemic therapies and, if possible, the performance of histology-specific, prospective, randomized clinical trials to advance the field.

The FDA granted orphan drug designation for a developmental agent known as GPX-150, an analog of doxorubicin currently being tested for use in advanced or metastatic soft-tissue sarcoma.

A phase II trial of dasatinib found that the drug did not produce strong clinical benefit in most types of advanced sarcoma, though it may have activity in undifferentiated pleomorphic sarcoma.

The presence of a TP53 mutation was associated with improved survival in patients with advanced soft-tissue sarcoma who were treated with VEGFR inhibition.


Subscribe to Sarcoma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.